Compare AbCellera Biologics Inc (ABCL) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Motorola Solutions Inc — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Motorola Solutions Inc trades at $422.22 (market cap $70.42B). The key difference: Motorola Solutions Inc is far larger — about 30× AbCellera Biologics Inc's market cap, and Motorola Solutions Inc pays a 1.14% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MSI | |
|---|---|---|
Market Cap | $2.35B | $70.42B |
Sector | Health | Technology |
52-Week High | $8.12 | $490.30 |
52-Week Low | $2.78 | $363.83 |
Enterprise Value | $1.99B | $79.12B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Motorola Solutions (MSI) trades at $424.21, up 0.37% with strong technical momentum and bullish analyst sentiment. The company demonstrates robust fundamentals with 17.61% net margins and consistent earnings beats, supported by recent AI expansion initiatives and a $1.5B acquisition of D-Fend Solutions. Revenue growth has accelerated from $9.1B in 2022 to $11.7B in 2025.
MSI presents a compelling growth story with AI-driven public safety expansion and strong institutional support, though elevated valuation multiples and increased capital expenditures pose risks. The consensus price target of $512.33 suggests 21% upside potential, supported by 71% analyst buy ratings and positive technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
